Gestational Diabetes in Uganda and India Improving Screening and Self-management


This trial will evaluate a package of three interconnected educational/behavioural interventions aimed at: a) improving knowledge and skills of GDM guidelines and skills of health providers; b) raising awareness of importance of GDM screening among pregnant women and their families; and c) improving confidence and skills in self-management among those diagnosed with GDM. The interventions will be delivered through the medium of film as they are low-cost and scalable, and are particularly suitable for people who are not very literate, making them ideal for low- and middle-income countries (LMICs).

The research will be carried out in Uganda (Entebbe) and India (Bengaluru). A careful contextual analysis will precede the development of a culturally-tailored film-based intervention for each setting, which will be iteratively refined using qualitative research methods till it is fit for purpose. The effectiveness of the intervention will be evaluated in independent cluster randomised trials, involving ~10,000 pregnant women across 30 maternity units at each site. The films will be made available in the intervention arm facilities: for viewing by doctors and nurses at their meetings, for continual screening in waiting areas of antenatal clinics, and during group education sessions (and personal mobile use) for GDM patients. Where video/projection facilities are unavailable, small low-cost projectors will be made available. Control arms will follow usual care practices.

The principal research question is whether a low-cost educational/behavioural intervention delivered through a package of culturally-tailored films can provide scalable improvements in timely detection and management of GDM. This will be evaluated through assessing three endpoints: a) detection of GDM at 32 weeks of; b) glycaemic control (fasting glucose) in women with GDM at ~34 weeks of pregnancy; and c) adverse perinatal outcomes associated with GDM. Interviews will be conducted with women and health providers to help understand how and why the intervention may be (or may not be) successful. The ultimate aim of the project is to contribute to scientific evidence underpinning the use of films in cost-effectively scaling up behavioural interventions in low literacy settings.

Full Title of Study: “Gestational Diabetes in Uganda and India: Design and Evaluation of Educational Films for Improving Screening and Self-management”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 1, 2021


  • Behavioral: Intervention
    • Three film-based components: Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric and neonatal care, and lifestyle counselling. These films will be screened 6-monthly at routine professional development meetings. Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The films will be culturally tailored and will be screened in waiting areas of antenatal clinics. Structured diabetes self-management education programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at weekly group sessions and optimised for viewing on mobile devices.

Arms, Groups and Cohorts

  • Experimental: Intervention
    • A package of three interconnected educational/behavioural film-based interventions will developed for delivery at the cluster (clinic) level. The aim of the three components will be as follows: a) improving knowledge of GDM guidelines and skills among health providers involved in GDM management, b) raising awareness of GDM and the importance of screening among pregnant women and their family members, and c) improving confidence and skills in self-management of GDM among women diagnosed.
  • No Intervention: Control
    • Usual care practices.

Clinical Trial Outcome Measures

Primary Measures

  • GDM diagnosis
    • Time Frame: 32 weeks of pregnancy
    • Proportion of women with a diagnosis of GDM. Self-reported via telephone contact.
  • Mean fasting blood sugar (women with GDM)
    • Time Frame: 34 weeks of pregnancy
    • Mean fasting blood sugar in women diagnosed with GDM. Measured at clinic visit.

Secondary Measures

  • Adverse perinatal outcomes (composite measure)
    • Time Frame: 6 weeks post-partum
    • Proportion of women with adverse perinatal outcomes related to GDM (composite of Caesarean section delivery, perinatal mortality, and infant hospitalization within 6 weeks of delivery). Self-reported via telephone contact post delivery.
  • HbA1c (women with GDM)
    • Time Frame: 34 weeks.
    • Average blood sugar level in women diagnosed with GDM. Measured at clinic visit.

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women aged 18 or over attending for antenatal care at participating health facilities.
  • Pregnant women willing and able to give informed consent.

Exclusion Criteria

  • Pregnant women <18 years
  • No informed consent

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • London School of Hygiene and Tropical Medicine
  • Collaborator
    • MRC/UVRI Uganda Research Unit on Aids
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Sanjay Kinra, Principal Investigator, London School of Hygiene and Tropical Medicine
  • Overall Contact(s)
    • Laura Oakley, 00 44 207 9272901,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.